Custom Patient Cohorts

Unparalleled Access to Genomically-Defined Patients

Define your own custom cohort through our global partnerships, which include our recent acquisition of Genomics Medicine Ireland.

Custom Patient Cohorts

Accelerate your target identification

Select for therapeutic area, geographic location, or ethnic background. Cohorts contain genotypic data enriched with deep phenotypic data, and are statistically powered to distinguish signal from noise.

Powered for statistical significance

Cohorts powered with more than 5,000 patients for many diseases or clinical features. Control groups of up to 15,000 healthy individuals.

Patient consent and re-contact

Ability to re-contact fully consented patients for follow-up phenotypes, outcomes, and further samples. We ensure patient consent, and compliance with data protection and privacy.

Digitize your samples

Whole Genome and Whole Exome Sequencing from FFPE samples, blood, saliva, tissue, cultured cells, or dried blood spots.

Scalable GORdb platform

Our proprietary platform provides a holistic view of your own private data with that from public genomic databanks.

Powerful analytics crafted for genomics

Analytics and AI trained on multi-omic and phenotypic data. Proven in target discovery, drug response signatures, and population genomics.

Retrospective and Prospective Trials

Can be used for both prospective and retrospective studies

Available Cohort Programs

Europe, Asia, N. America

Oncology
Diabetes & Complications
Autoimmune/Rheumatology
Respiratory
Liver Disease
ICU Medicine
Nervous System
Medical Dermatology
Psychiatry
Cosmetic Dermatology
Rare Pediatric Disorders

Oncology

Paired Primary v Metastatic I/O and Therapeutic Resistance

  • Glioma: advanced vs. primary, GBM invasive edge vs. core
  • NSCLC, small cell lung carcinoma
  • Breast cancer
  • Colorectal cancer
  • Colon cancer
  • Prostate cancer
  • Renal cancer
  • Melanoma
  • Pancreatic cancer
  • Non-Hodgkin's lymphoma
  • Hepatocellular carcinoma
  • Esophageal, gastric carcinoma
  • Ovarian carcinoma
  • Endometrial carcinoma
  • AML/MDS
  • Multiple myeloma

Diabetes & Complications

  • Diabetic nephropathy
  • Diabetic retinopathy
  • Diabetic neuropath
  • Type 1 diabetes
  • Type 2 diabetes
  • Obesity and morbid obesity
  • Macrovascular complications
  • Cardiovascular
  • Heart failure (preserved and reduced ejection fraction)
  • Premature atherosclerosis & resistance to atherosclerosis
  • Sudden cardiac death
  • Aortic aneurysm

Autoimmune/Rheumatology

  • Crohn's
  • Ankylosing spondylitis
  • Rheumatoid arthritis
  • Psoriasis
  • Psoriatic arthritis
  • Lupus nephritis
  • Lupus
  • Ulcerative Colitis
  • Sjogren's syndrome
  • Systemic sclerosis
  • Osteoarthritis

Respiratory

  • Ashtma
  • COPD
  • Idiopathic pulmonary fibriosis and interstitial lung disease
  • ARDS

ICU Medicine

  • Sepsis
  • Acute renal failure
  • ARDS
  • Disuse muscular atrophy

Nervous System

  • Alzheimer's disease
  • Multiple sclerosis
  • Neuropathic pain
  • Parkinson's disease
  • Frontotemporal dementia
  • Drug-resistance epilepsy

Medical Dermatology

  • Atopic dermatitis (childhood and persistent into adulthood)
  • Psoriasis
  • Acne
  • Hidradenitis suppurativa
  • Chronic spontaneous urticaria

Psychiatry

  • Bipolar disease
  • Major depression
  • Schizophrenia
  • ADHD

Cosmetic Dermatology

  • Premature wrinkles vs protection from wrinkles
  • Rosacea
  • Melasma

Rare Pediatric Disorders

  • Drug-resistant epilepsy
  • Autoimmune diseases
  • Myopathies
Data connecting across the globe

Our differentiated approach

  • Partner with healthcare providers, biopharma, government, foundations, and patient groups
  • Focus on homogeneous populations for better signal to noise resolution
  • Use WGS to fully leverage the genome
  • Disease specialists curate and validate deep phenotypic data
  • Supported by our full catalog of products and team of experts

Related items


Using Powered Cohorts to Speed Drug Discovery and Development

With the recent acquisition of Genomics Medicine Ireland (GMI, in Dublin), WuXi NextCODE is realizing the vision of turning advancements in genomics into improvements in drug discovery and ultimately population health, providing benefit to patients around the world.

Read More

The Rise of Population-scale Genomic Projects for Pharma R&D Investments

With the announced $400 million investment from global investors including the Irish sovereign fund, WuXi NextCODE announced that GMI would whole genome sequence and collect detailed medical data on 400,000 Irish volunteers covering 60 major diseases, partnering with life sciences companies to analyse the data for insights.

Read More